Setipiprant
Phase 2Small molecule
Idorsia Pharmaceuticals Ltd.Setipiprant is one of 48 small molecule programs targeting Androgenetic Alopecia. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Arcoxia
NovartisPreclinical
Setipiprant
Idorsia Pharmaceuticals Ltd.Phase 2
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Setipiprant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company